This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Vyvanse
Smoothest amphetamine PK in the class — L-lysine peptide bond is cleaved by red-blood-cell aminopeptidase to release d-amphetamine over…
Aliases (9)
Overview
What is Vyvanse?
Vyvanse (lisdexamfetamine) is a prodrug of d-amphetamine, FDA-approved for ADHD and binge eating disorder. The lysine-bound prodrug structure must be cleaved enzymatically in red blood cells, producing slow steady-state amphetamine release with reduced abuse liability vs immediate-release stimulants.
Key Benefits
Improves attention, executive function, and impulse control in ADHD; reduces binge eating frequency in BED; smooth 10-13 hour duration without IR-amphetamine spikes; lower abuse liability than IR amphetamine because crushing/snorting does not increase peak.
Mechanism of Action
Lisdexamfetamine is hydrolyzed by red blood cell peptidases to release d-amphetamine and L-lysine. D-amphetamine then enters monoaminergic neurons via DAT/NET, reverses these transporters, and triggers dopamine and norepinephrine release from vesicles via VMAT2 substrate competition. Net effect: large increases in synaptic DA and NE in PFC and reward circuits.
Pharmacokinetics
▸Brand options6 known
StatusSchedule II (US DEA, since 2007) | Schedule II (Canada CDSA) | Class B Pt II (UK) | Schedule 8 (AUS)
Research Indications
IV/intranasal route blocked
IV LDX 50mg in supervised abuse-liability trials produced no greater "drug liking" than placebo, while IV d-amphetamine 20mg produced sig…
Oral route partially protected, not fully
This is the nuance the marketing softens. Oral LDX still produces euphoria and drug-liking effects above placebo, and its oral abuse liab…
DAT/NET reuptake inhibition + reverse transport
d-amphetamine enters monoamine terminals via DAT/NET, displaces vesicular dopamine and norepinephrine via VMAT2 inhibition, and triggers …
MAO inhibition (modest)
d-amphetamine weakly inhibits MAO-A, prolonging monoamine action.
Cortical and striatal effects
DA elevation in nucleus accumbens drives reinforcement; PFC NE/DA elevation drives executive function and sustained attention.
Peptide Interactions
(5-10mg/day): May slow stimulant tolerance via NMDA antagonism. Anecdotal + small clinical signal. Useful if Vyvanse becomes part of long-term protocol.
(PRN): Substrate for catecholamine synthesis. Some users report less crash and less tolerance buildup with intermittent tyrosine support. Low-evidence but me…
(the canonical stack covers this): Helps with bruxism, sleep, BP modulation.
(the canonical stack covers this): Smooths the adrenergic edge, may reduce anxiety on dose days.
(the canonical stack covers this): General neuroprotection during stimulant exposure.
(the canonical stack covers this): Glutathione support, mild glutamatergic modulation. Some evidence for reducing stimulant abuse-related craving in cocaine/…
Hypertensive crisis risk. Hard contraindication.
Loses MAO-B selectivity → same hypertensive crisis risk. Low-dose selegiline (1-2.5mg) is safer but always with caution and monitoring.
Serotonin syndrome risk. Manageable with monitoring but real.
Stacked cardiovascular load; no additional cognitive benefit; receptor saturation. The encyclopedia explicitly flags Vyvanse + Dexedrine as a "stim + stim" c…
Theoretical glutamatergic stacking risk; insufficient data, default to caution.
Defeats the stimulant; risk of binge-cycle pattern.
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- Day 1PK-driven acute peak per administration. Verify dose tolerated.
- Week 1Steady-state reached for most daily-dosed pharma.
- Week 2-4Therapeutic effect established; titration window if needed.
- Long-termPeriodic monitoring per drug class (labs, BP, ECG as applicable).
Side Effects & Safety 17
Side Effects
- 1Decreased appetite — 30-40% in trials. Often the most disruptive side effect for athletes (the user: training calorie targets 3500+ kcal/day, MMA performance depends on sustained fueling).
- 2Insomnia / trouble sleeping — 13-27% in clinical studies. Higher with afternoon dosing.
- 3Dry mouth — common, most users.
- 4Anxiety / irritability — 5-15%.
- 5Headache — 10-15%.
- 6Weight loss — small but consistent (~1-3 kg over 4-12 weeks).
- 7Increased heart rate — typically +10-15 bpm.
- 8Increased blood pressure — typically +5-10 mmHg systolic.
- 9Nausea, abdominal pain, vomiting (most pronounced in pediatric trials)
- 10Diarrhea or constipation
- 11Dizziness
- 12Tremor, restlessness, akathisia
- 13Bruxism / jaw tension
- 14Erectile dysfunction, decreased libido
- 15Mood swings, dysphoria, irritability (especially during taper at end of dose)
- 16Sweating
- 17Tachycardia (>100 bpm at rest)
When to Stop
- Sudden cardiac events — sudden death has been reported in patients with structural cardiac abnormalities or pre-existing cardiomyopathy on amphetamines. Black box warning in the US label. Pre-treatment ECG and family history screening recommended for adults starting any amphetamine.
- Serotonin syndrome — when combined with serotonergic agents (SSRIs, SNRIs, MAOIs, triptans, MDMA, tramadol). Amphetamines have weak SERT effects; clinically meaningful SS risk is mostly with MAOI/SSRI co-administration.
- Stimulant-induced psychosis or mania — rare in non-vulnerable individuals; higher in undiagnosed bipolar or family history of psychotic illness.
- Peripheral vasculopathy / Raynaud's phenomenon — rare but documented at higher doses and chronic use.
- Tic emergence or worsening — relevant if Tourette's family history.
- Stevens-Johnson Syndrome / DRESS — rare, no specific signal vs other amphetamines.
- Tooth damage — chronic dry mouth + bruxism over years can damage enamel; mitigation = mouthguard at night, dental hygiene.
- Growth suppression in pediatric populations — small effect (~1-2 cm height over years), generally recovers post-discontinuation. Less relevant for adults.
- Dependence and withdrawal — physical and psychological dependence is real with chronic daily use. Withdrawal: fatigue, hypersomnia, depression, anhedonia, increased appetite for several weeks.
- Weeks 1-4: dose titration phase — track HR/BP daily, sleep onset, appetite, mood. If any side effect intolerable, slow titration or discontinue.
- First 6 months: monitor weight monthly, repeat HR/BP. ECG if any new palpitations or chest discomfort.
- Indefinite (chronic use): annual ECG, BP/HR check, dental check (bruxism), screen for tolerance/dependence, periodically reassess whether benefit still > cost.
References
Lisdexamfetamine — Wikipedia 2026
current PK, mechanism, regulatory, brand names. Solid first-pass reference.
View StudyPennick 2014 — RBC peptidase activation of LDX
landmark paper establishing RBC cytosolic metallo-aminopeptidase as activation mechanism (not GI peptidases).
View StudySharman 2016 — LDX hydrolysis in sickle cell disease RBCs
confirms hematocrit dependence; only matters at <10% normal RBC.
View StudyPennick 2010 — LDX prodrug mechanism review
comprehensive prodrug pharmacology.
View StudyComerford 2016 — LDX prodrug delivery review (PMC)
clinical pharmacology synthesis; cited in encyclopedia.
View StudyKämmerer 2024 — Comparative pharmacology and abuse potential of oral d-amphetamine vs LDX
definitive 2024 review concluding oral abuse liability of LDX is comparable to d-amphetamine.
View StudyReynolds et al. 2023 — Amphetamine disrupts dopamine axon growth in adolescent male mice (Nat Comms)
DCC/Netrin-1 mechanism; sex-specific.
View StudyReynolds et al. 2025 — Sex-specific mesolimbic DA phenotype rerouted to PFC after adolescent amphetamine (Comm Biol Dec 2025)
replication + extension showing enduring vulnerability.
View StudyCuesta et al. 2023 — Rewiring the future: adolescent drugs and DA axon growth (Springer)
review tying mechanism to mental illness vulnerability.
View StudyFDA Vyvanse approval and label (2017 update)
current FDA-approved indications, dosing, warnings.
View StudyDailyMed — Vyvanse capsule and chewable monograph
current prescribing information.
View StudyLisdexamfetamine review for BED — PubMed 2017
clinical efficacy review for BED indication.
View StudyFDA BED approval announcement (Jan 2015)
historical record of phase 3 trial outcomes.
View StudyManagement of Binge Eating Disorder — ACOFP 2024
current 2024 BED treatment review confirming LDX as only FDA-approved option.
View StudyDrugPatentWatch — LDX patent timeline
patent expiry Feb 2023, generic launch Aug 2023.
View StudyASHP — Lisdexamfetamine Dimesylate shortage detail
active 2026 shortage; Amneal, Hikma, Mallinckrodt, Solco affected.
View StudyMedfinder — Vyvanse shortage 2026 update
current shortage status, brand availability, copay options.
View StudyTakeda Patient Support copay program
$30/month brand Vyvanse with commercial insurance; Help at Hand PAP for uninsured.
View StudyAdditudeMag — DEA quota expansion announcement
2025-2026 quota increases context.
View StudyFrontiers Psychiatry 2025 — LDX vs guanfacine in pediatric ADHD
recent comparative cognitive data.
View StudyInternational Health Sciences Review 2026 — Psychostimulants in adults: medical vs cognitive optimization
current framing of stimulant use beyond diagnosis.
View StudyAdderall vs Vyvanse — Drugs.com clinical comparison
patient-facing differences summary.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.